Matches in SemOpenAlex for { <https://semopenalex.org/work/W2549950263> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2549950263 endingPage "vi138" @default.
- W2549950263 startingPage "vi138" @default.
- W2549950263 abstract "Background: Extrapulmonary poorly differentiated neuroendocrine carcinomas (NECs) clinically resemble a small cell lung cancer (SCLC), where carboplatin has been reported as active as cisplatin, combined with etoposide. We studied carboplatin/etoposide combination in patients with extrapulmonary NEC. Patients and methods: Consecutive patients with histological diagnosis of extrapulmonary unresectable locally advanced or metastatic NEC were enrolled. Overall response rate (ORR) was primary endpoint, whereas disease control rate (DCR), toxicity, progression free survival (PFS) and overall survival (OS) were secondary endpoints. Results: Forty-six patients were treated with Etoposide 100 mg/m2/day over three days and Carboplatin AUC 4-6 on day 1, every three weeks. Median age was 58 years (range 23-75). Thirty-nine patients were untreated and 7 pre-treated. Overall response rate was 54% (6% complete responses and 48% partial responses). Disease control rate was 78% (ORR + stable disease). Neutropenia was the most frequent grade 3-4 toxicity (22%), with 4 episodes of febrile neutropenia (9%). All type grade 3-4 toxicities occurred in the 33% of patients, leading to chemotherapy discontinuation in 2 cases (4%). Globally, PFS was 5 months (95% CI: 4.2 - 6.9) and OS 14 months (95% CI: 11.5 - 21.1). Conclusions: Carboplatin/etoposide combination is active and manageable in patients with extrapulmonary NEC. In a cross-study comparison, it is worth noting that our activity data are similar to, or even higher than, those reported for cisplatin/etoposide. Based on different toxicity profile, carboplatin could be considered as a possible alternative to cisplatin in this clinical setting." @default.
- W2549950263 created "2016-11-30" @default.
- W2549950263 creator A5020435379 @default.
- W2549950263 creator A5053190653 @default.
- W2549950263 creator A5056874648 @default.
- W2549950263 creator A5064083940 @default.
- W2549950263 creator A5071532685 @default.
- W2549950263 creator A5078823780 @default.
- W2549950263 creator A5084629809 @default.
- W2549950263 creator A5085512648 @default.
- W2549950263 date "2015-10-01" @default.
- W2549950263 modified "2023-10-17" @default.
- W2549950263 title "Carboplatin and etoposide chemotherapy in extrapulmonary poorly differentiated neuroendocrine carcinomas" @default.
- W2549950263 doi "https://doi.org/10.1093/annonc/mdv348.20" @default.
- W2549950263 hasPublicationYear "2015" @default.
- W2549950263 type Work @default.
- W2549950263 sameAs 2549950263 @default.
- W2549950263 citedByCount "0" @default.
- W2549950263 crossrefType "journal-article" @default.
- W2549950263 hasAuthorship W2549950263A5020435379 @default.
- W2549950263 hasAuthorship W2549950263A5053190653 @default.
- W2549950263 hasAuthorship W2549950263A5056874648 @default.
- W2549950263 hasAuthorship W2549950263A5064083940 @default.
- W2549950263 hasAuthorship W2549950263A5071532685 @default.
- W2549950263 hasAuthorship W2549950263A5078823780 @default.
- W2549950263 hasAuthorship W2549950263A5084629809 @default.
- W2549950263 hasAuthorship W2549950263A5085512648 @default.
- W2549950263 hasBestOaLocation W25499502631 @default.
- W2549950263 hasConcept C126322002 @default.
- W2549950263 hasConcept C141071460 @default.
- W2549950263 hasConcept C143998085 @default.
- W2549950263 hasConcept C203092338 @default.
- W2549950263 hasConcept C2776694085 @default.
- W2549950263 hasConcept C2777063308 @default.
- W2549950263 hasConcept C2778119113 @default.
- W2549950263 hasConcept C2778239845 @default.
- W2549950263 hasConcept C2778715236 @default.
- W2549950263 hasConcept C2778850193 @default.
- W2549950263 hasConcept C2781451048 @default.
- W2549950263 hasConcept C535046627 @default.
- W2549950263 hasConcept C71924100 @default.
- W2549950263 hasConcept C90924648 @default.
- W2549950263 hasConceptScore W2549950263C126322002 @default.
- W2549950263 hasConceptScore W2549950263C141071460 @default.
- W2549950263 hasConceptScore W2549950263C143998085 @default.
- W2549950263 hasConceptScore W2549950263C203092338 @default.
- W2549950263 hasConceptScore W2549950263C2776694085 @default.
- W2549950263 hasConceptScore W2549950263C2777063308 @default.
- W2549950263 hasConceptScore W2549950263C2778119113 @default.
- W2549950263 hasConceptScore W2549950263C2778239845 @default.
- W2549950263 hasConceptScore W2549950263C2778715236 @default.
- W2549950263 hasConceptScore W2549950263C2778850193 @default.
- W2549950263 hasConceptScore W2549950263C2781451048 @default.
- W2549950263 hasConceptScore W2549950263C535046627 @default.
- W2549950263 hasConceptScore W2549950263C71924100 @default.
- W2549950263 hasConceptScore W2549950263C90924648 @default.
- W2549950263 hasLocation W25499502631 @default.
- W2549950263 hasOpenAccess W2549950263 @default.
- W2549950263 hasPrimaryLocation W25499502631 @default.
- W2549950263 hasRelatedWork W1969260054 @default.
- W2549950263 hasRelatedWork W1984418710 @default.
- W2549950263 hasRelatedWork W2170402962 @default.
- W2549950263 hasRelatedWork W2243956249 @default.
- W2549950263 hasRelatedWork W2253280322 @default.
- W2549950263 hasRelatedWork W2471989939 @default.
- W2549950263 hasRelatedWork W2472861731 @default.
- W2549950263 hasRelatedWork W2609842262 @default.
- W2549950263 hasRelatedWork W3013194840 @default.
- W2549950263 hasRelatedWork W4254740740 @default.
- W2549950263 hasVolume "26" @default.
- W2549950263 isParatext "false" @default.
- W2549950263 isRetracted "false" @default.
- W2549950263 magId "2549950263" @default.
- W2549950263 workType "article" @default.